Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (July 1982). "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products". Nature. 298 (5871): 240–4. Bibcode:1982Natur.298..240A. doi:10.1038/298240a0. PMID6283379. S2CID24188834.
Rezaeian AH, Isokane T, Nishibori M, Chiba M, Hiraiwa N, Yoshizawa M, Yasue H (October 2009). "alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites". Brain & Development. 31 (9): 682–93. doi:10.1016/j.braindev.2008.10.011. PMID19062206. S2CID21635386.
Chen LJ, Zhang FG, Li J, Song HX, Zhou LB, Yao BC, et al. (January 2010). "Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury". Journal of Clinical Neuroscience. 17 (1): 87–91. doi:10.1016/j.jocn.2009.03.042. PMID19969463. S2CID29249307.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. (June 2002). "International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors". Pharmacological Reviews. 54 (2): 233–46. doi:10.1124/pr.54.2.233. PMID12037140. S2CID17302944.
Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR (October 2004). "Calcitonin gene-related peptide and its role in migraine pathophysiology". European Journal of Pharmacology. 500 (1–3): 315–30. doi:10.1016/j.ejphar.2004.07.035. PMID15464043.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN (June 2018). "CGRP as the target of new migraine therapies - successful translation from bench to clinic". Nature Reviews. Neurology. 14 (6): 338–350. doi:10.1038/s41582-018-0003-1. PMID29691490. S2CID13810025.
Goadsby PJ, Edvinsson L (June 1994). "Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies". Brain. 117 ( Pt 3) (3): 427–34. doi:10.1093/brain/117.3.427. PMID7518321.
Goadsby PJ, Edvinsson L, Ekman R (August 1990). "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache". Annals of Neurology. 28 (2): 183–7. doi:10.1002/ana.410280213. PMID1699472. S2CID12568270.
Pardridge WM (December 2017). "Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology". BioDrugs. 31 (6): 503–519. doi:10.1007/s40259-017-0248-z. PMID29067674. S2CID9282946.
Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A (September 2016). "Pharmacokinetics interactions of monoclonal antibodies". Pharmacological Research. 111: 592–599. doi:10.1016/j.phrs.2016.07.015. PMID27438459.
Wang W, Wang EQ, Balthasar JP (November 2008). "Monoclonal antibody pharmacokinetics and pharmacodynamics". Clinical Pharmacology and Therapeutics. 84 (5): 548–58. doi:10.1038/clpt.2008.170. PMID18784655. S2CID7994962.
Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M (March 2019). "Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety". Drugs. 79 (4): 417–431. doi:10.1007/s40265-019-01069-1. PMID30793254. S2CID67790108.
Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E (November 2018). "From LBR-101 to Fremanezumab for Migraine". CNS Drugs. 32 (11): 1025–1037. doi:10.1007/s40263-018-0579-4. PMID30311143. S2CID52962394.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (July 1982). "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products". Nature. 298 (5871): 240–4. Bibcode:1982Natur.298..240A. doi:10.1038/298240a0. PMID6283379. S2CID24188834.
Rezaeian AH, Isokane T, Nishibori M, Chiba M, Hiraiwa N, Yoshizawa M, Yasue H (October 2009). "alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites". Brain & Development. 31 (9): 682–93. doi:10.1016/j.braindev.2008.10.011. PMID19062206. S2CID21635386.
Chen LJ, Zhang FG, Li J, Song HX, Zhou LB, Yao BC, et al. (January 2010). "Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury". Journal of Clinical Neuroscience. 17 (1): 87–91. doi:10.1016/j.jocn.2009.03.042. PMID19969463. S2CID29249307.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. (June 2002). "International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors". Pharmacological Reviews. 54 (2): 233–46. doi:10.1124/pr.54.2.233. PMID12037140. S2CID17302944.
Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR (October 2004). "Calcitonin gene-related peptide and its role in migraine pathophysiology". European Journal of Pharmacology. 500 (1–3): 315–30. doi:10.1016/j.ejphar.2004.07.035. PMID15464043.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN (June 2018). "CGRP as the target of new migraine therapies - successful translation from bench to clinic". Nature Reviews. Neurology. 14 (6): 338–350. doi:10.1038/s41582-018-0003-1. PMID29691490. S2CID13810025.
Goadsby PJ, Edvinsson L (June 1994). "Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies". Brain. 117 ( Pt 3) (3): 427–34. doi:10.1093/brain/117.3.427. PMID7518321.
Goadsby PJ, Edvinsson L, Ekman R (August 1990). "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache". Annals of Neurology. 28 (2): 183–7. doi:10.1002/ana.410280213. PMID1699472. S2CID12568270.
Pardridge WM (December 2017). "Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology". BioDrugs. 31 (6): 503–519. doi:10.1007/s40259-017-0248-z. PMID29067674. S2CID9282946.
Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A (September 2016). "Pharmacokinetics interactions of monoclonal antibodies". Pharmacological Research. 111: 592–599. doi:10.1016/j.phrs.2016.07.015. PMID27438459.
Wang W, Wang EQ, Balthasar JP (November 2008). "Monoclonal antibody pharmacokinetics and pharmacodynamics". Clinical Pharmacology and Therapeutics. 84 (5): 548–58. doi:10.1038/clpt.2008.170. PMID18784655. S2CID7994962.
Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M (March 2019). "Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety". Drugs. 79 (4): 417–431. doi:10.1007/s40265-019-01069-1. PMID30793254. S2CID67790108.
Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E (November 2018). "From LBR-101 to Fremanezumab for Migraine". CNS Drugs. 32 (11): 1025–1037. doi:10.1007/s40263-018-0579-4. PMID30311143. S2CID52962394.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (July 1982). "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products". Nature. 298 (5871): 240–4. Bibcode:1982Natur.298..240A. doi:10.1038/298240a0. PMID6283379. S2CID24188834.
Rezaeian AH, Isokane T, Nishibori M, Chiba M, Hiraiwa N, Yoshizawa M, Yasue H (October 2009). "alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites". Brain & Development. 31 (9): 682–93. doi:10.1016/j.braindev.2008.10.011. PMID19062206. S2CID21635386.
Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. (1983). "Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing". Nature. 304 (5922): 129–35. Bibcode:1983Natur.304..129R. doi:10.1038/304129a0. PMID6346105. S2CID4322278.
Chen LJ, Zhang FG, Li J, Song HX, Zhou LB, Yao BC, et al. (January 2010). "Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury". Journal of Clinical Neuroscience. 17 (1): 87–91. doi:10.1016/j.jocn.2009.03.042. PMID19969463. S2CID29249307.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. (June 2002). "International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors". Pharmacological Reviews. 54 (2): 233–46. doi:10.1124/pr.54.2.233. PMID12037140. S2CID17302944.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN (June 2018). "CGRP as the target of new migraine therapies - successful translation from bench to clinic". Nature Reviews. Neurology. 14 (6): 338–350. doi:10.1038/s41582-018-0003-1. PMID29691490. S2CID13810025.
Goadsby PJ, Edvinsson L, Ekman R (August 1990). "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache". Annals of Neurology. 28 (2): 183–7. doi:10.1002/ana.410280213. PMID1699472. S2CID12568270.
Pardridge WM (December 2017). "Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology". BioDrugs. 31 (6): 503–519. doi:10.1007/s40259-017-0248-z. PMID29067674. S2CID9282946.
Wang W, Wang EQ, Balthasar JP (November 2008). "Monoclonal antibody pharmacokinetics and pharmacodynamics". Clinical Pharmacology and Therapeutics. 84 (5): 548–58. doi:10.1038/clpt.2008.170. PMID18784655. S2CID7994962.
Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M (March 2019). "Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety". Drugs. 79 (4): 417–431. doi:10.1007/s40265-019-01069-1. PMID30793254. S2CID67790108.
Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E (November 2018). "From LBR-101 to Fremanezumab for Migraine". CNS Drugs. 32 (11): 1025–1037. doi:10.1007/s40263-018-0579-4. PMID30311143. S2CID52962394.